Enovix Corp 8-K

What Happened

• Enovix Corporation announced on July 9, 2026 (filed via Form 8-K) that Dr. Michael Vyvoda will join as Chief Operating Officer effective July 29, 2026. Dr. Vyvoda’s background includes recent COO roles at Magrathea Metals (Jul 2025–Jul 2026) and Aircapture (Sep 2023–Jul 2025), and he led product operations for Apple’s AirPods (Apr 2018–Aug 2023). The company and Dr. Vyvoda entered into an employment agreement that will be filed as an exhibit to Enovix’s next Form 10-Q.

Key Details

• Start date: July 29, 2026 (effective date); equity grant date: August 5, 2026.
• Base salary: $440,000 per year.
• Target annual discretionary cash bonus: 60% of base salary (performance-based).
• Equity: RSUs with a fair market value of $4,000,000 on the grant date (25% vests after 12 months, remainder vests in equal quarterly installments), plus $100,000 in RSUs that vest immediately on the grant date.
• Severance if terminated without Cause or resigns for Good Reason (not in connection with a Change of Control): nine months’ base salary cash, nine months of health coverage, a pro‑rated bonus, and eligibility for accelerated vesting of certain equity awards; additional accelerated vesting applies if termination is in connection with a Change of Control.
• Dr. Vyvoda executed Enovix’s standard officer indemnification agreement.

Why It Matters

• This is a material executive change: Enovix has added an experienced operations leader with high-volume manufacturing and product operations experience (including Apple’s AirPods), which is relevant as the company scales production.
• Compensation is heavily equity‑based (multi‑million dollar RSU grant), aligning the COO’s incentives with shareholders but also representing potential future dilution. Severance and change‑of‑control provisions could create one‑time cash or equity acceleration obligations under certain termination scenarios.
• Investors should note the timing of the grant (Aug 5, 2026) and that the full Employment Agreement will be filed with the next Form 10-Q for further details.